Posted in the last 24 hours

Fresh from the desks

gene therapy

The First Treatment for Sanfilippo Syndrome Type A Arrived, and It Came as a Gene Therapy

The FDA approved Ultragenyx's Fayuvi, the first therapy for the fatal childhood disorder, on the strength of a single-arm trial compared against a natural history cohort, with the clearest benefit in children treated before regression.

By James T.·September 17, 2026·8 min read
election law

The Missouri Map Fight Reached the Appeals Court the Same Week Ballots Had to Mail

An Eighth Circuit panel heard Republican arguments to revive Missouri's 2025 congressional map, but the Supreme Court's stay and the Friday military-ballot deadline make the real decision a race against the calendar.

By Victoria C.·September 17, 2026·8 min read
markets

The SEC Just Opened a Five-Year Door to Tokenized Stocks by Exemption, Not Legislation

A new SEC order lets trading venues issue tokenized versions of publicly traded U.S. stocks under a five-year exemption, with dividend and voting rights attached, two days after the Clarity Act failed in the Senate.

By Vasil V.·September 17, 2026·8 min read
neurology

Novartis Halted Its ALS Drug After the Biomarkers Moved and the Patients Did Not

The Phase 2 ASTRALS trial of VHB937 missed both endpoints in 251 people with early ALS, ending the TREM2-targeting program and marking Novartis's fourth clinical setback in under a month.

By James T.·September 17, 2026·8 min read
women's health

Testosterone Prescriptions for Women Nearly Tripled While the FDA Had No Approved Product. The Review Just Opened

The FDA held a public workshop on testosterone therapy for menopausal women as prescriptions surged 146 percent in three years, and the central question is what evidence would be enough for the first approved product.

By James T.·September 17, 2026·8 min read
rates

The 30-Year Mortgage Jumped to 6.95 Percent in the Week the Fed Hiked

The average 30-year fixed mortgage rate rose 19 basis points this week to 6.95 percent, the market's fast repricing after the Federal Reserve's first hike in three years, and buyers are now credit-checked against the new level.

By Vasil V.·September 17, 2026·8 min read
rates

Denmark Opened Its First 5 Percent Mortgage Since 2023, and the Fed Hike Helped Push It Open

Jyske Realkredit opened a 5 percent fixed-rate mortgage for the first time since December 2023 as rising oil prices, inflation expectations, and U.S. rates pushed the long-running 4 percent loan toward closure.

By Vasil V.·September 17, 2026·8 min read
enforcement

Oregon's COVID Fraud Prosecutors Have Recovered 22 Cents on Every Stolen Dollar

The U.S. Attorney's Office in Oregon announced more than $314 million recovered from pandemic relief fraud, roughly a fifth of the $1.6 billion in alleged losses, as a national push races the statutes of limitations.

By Victoria C.·September 17, 2026·8 min read
oncology

A Childhood Leukemia Trial Just Replaced Chemotherapy Instead of Adding to It

A 709-child trial published in the New England Journal of Medicine found that swapping two chemotherapy blocks for the immunotherapy blinatumomab nearly halved relapses while cutting severe infections from 69 to 24 percent.

By James T.·September 17, 2026·8 min read
B2B Research

Most Popular Research Articles

Intent Data

Intent Data Providers For B2B

Non-English intent signal is still under twenty percent of total volume industrywide, which means most platforms are seeing a fraction of the buying activity happening outside English language markets.

By Marko P.·8 min read
Knowledge Management

Knowledge Management Solutions

One vendor is explicitly competing on restraint, arguing that a plausible AI generated article that is subtly wrong is worse for a knowledge base than no article at all.

By Marko P.·8 min read
MDR

Managed Detection And Response Services

Forrester's own buyer guidance undercuts the AI pitch: providers are getting measurably more efficient, and there is little evidence yet that any of that efficiency is reaching customer pricing.

By Marko P.·8 min read
MDR Europe

Managed Detection And Response Services In Europe

Forrester's guidance to buyers is blunt: having a data centre in the EU answers one sovereignty question out of four, and most vendor pitches stop at the first.

By Marko P.·8 min read
Manufacturing Tech

Manufacturing Technology Services

Forrester frames 2026's binding constraint as a workforce that cannot be trained fast enough, which makes this a services category built around people more than platforms.

By Marko P.·8 min read
Market Intelligence

Market And Competitive Intelligence Platforms

Generative AI should have commoditized this category, and instead Forrester's criteria count kept climbing, because the moat was always licensed source access, not summarization.

By Marko P.·8 min read
Open Banking

Open Banking Intermediaries

Two of the category's most prominent independent players are now owned by the card networks they were supposed to route around.

By Marko P.·8 min read
Change Management

Organizational Change Management Services

Forrester's provider count nearly doubled in three years, and every other technology category in this series points at the same root cause: the software works and the organisation does not change.

By Marko P.·8 min read
PLM

Product Lifecycle Management Platforms For Discrete Manufacturers

Every reference customer for one vendor said they would buy again, which in PLM can mean genuine excellence or a customer base that has nowhere else to go once the evidence chain is built.

By Marko P.·8 min read
Announcements

News from Mavengity

Why Mavengity

Editorial standards you can check

Independently researched

We start from public rate filings, regulator guidance, and lender disclosures, not marketing copy.

Plain-English explanations

If a term needs a footnote, we explain it in the sentence instead of hiding it in the fine print.

Straight, not slanted

We flag trade-offs and blind spots, not just the upside, so you get the full picture before you decide.

Written for readers, not lenders

Mavengity is reader-supported and editorially independent from the products we cover.